The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.
The Leukemia & Lymphoma Society is becoming Blood Cancer United on August 28 in advance of Blood Cancer Awareness Month in September.
